Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

BMC Cancer · 2018 · PMC6258481 · PMID 30477470

Europe PMC DOI

hedged sentence

0.2630

closest p · 5.3× alpha

0.2630

boldest claim

The sentences

showed a trendP = 0.263not close (p > 0.1)

Median PFS showed a trend of superiority in c-Met overexpression group (15.2 versus 11.0 months, P = 0.263).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.